



PRESS RELEASE

## Collectis Reports Financial Results for Third Quarter and First Nine Months of 2017

- FDA has lifted the clinical hold from both Phase 1 trials of UCART123 in acute myeloid leukemia (AML) and in blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- Preliminary results of the first-in-human clinical trials of UCART19 will be presented at the 59th American Society of Hematology (ASH) annual meeting
- Completion on July 25, 2017 of the Nasdaq-listed IPO of Calyxt, a 79,8% owned subsidiary of Collectis - with \$64.4 million in gross proceeds to Calyxt
  - Cash<sup>1</sup> position of \$304 million as of September 30, 2017

**New York, N.Y. – November 13, 2017** – Collectis S.A. (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced its results for the three-month period ended September 30, 2017 and for the nine-month period ended September 30, 2017.

---

### Earnings Call Details

Collectis will host an earnings call on November 14, 2017 at 8:30am Eastern Time to discuss its financial results and provide a general business update.

#### Dial-In Numbers:

Live PARTICIPANT Dial-In (Toll-Free US & Canada): 877-407-3104  
Live PARTICIPANT Dial-In (International): +1 201-493-6792

#### Replay Information:

Conference ID #: 13625168  
Replay Dial-In (Toll Free US & Canada): 877-660-6853  
Replay Dial-In (International): +1 201-612-7415  
Expiration Date: 11/28/17

Webcast URL (Archived for 6 months): <http://collectis.equisolvewebcast.com/q3-2017>

---

<sup>1</sup> Cash position includes cash, cash equivalent and current financial assets.



## **Third Quarter 2017 and Recent Highlights**

### **Collectis - Therapeutics**

#### ***UCART123: Collectis' TALEN® gene-edited, allogeneic CAR T product candidate in AML and BPDCN Patients***

As of November 6, 2017, Collectis announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold, previously announced on September 4, 2017, on both Phase 1 trials of UCART123 product candidate in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). In connection with the lifting of the clinical hold, Collectis agreed with the FDA to certain revisions to be implemented in Phase 1 UCART123 protocols. Collectis is currently working with the investigators from Weill Cornell Medicine New York - Presbyterian Hospital and MD Anderson Cancer Center to obtain approval of the revised protocols from their respective institutional review boards in order to resume patient enrollment.

#### ***UCART19: TALEN® gene-edited, allogeneic CAR T product candidate in ALL patients, exclusively licensed to Servier***

Preliminary results of the first-in-human clinical trials of UCART19 will be presented at the 59<sup>th</sup> American Society of Hematology annual meeting (the "ASH Annual Meeting") to be held from December 9 to 12, 2017 in Atlanta, GA. Results from the UCART19 clinical trial in adult ALL patients will be presented orally by Reuben Benjamin, principal investigator for the trial and consultant hematologist at King's College Hospital, United Kingdom. Results from the UCART19 clinical trial in pediatric ALL patients will be presented during a poster session by Waseem Qasim, principal investigator for the trial and consultant in pediatric immunology and reader in cell and gene therapy at Great Ormond Street Hospital for Children, United Kingdom.

#### ***UCARTCS1, UCART22 & UCART123***

Three abstracts regarding other Company's off-the-shelf CAR T product candidates have been accepted for presentation at the 59<sup>th</sup> American Society of Hematology (ASH) Annual Meeting:

- *UCARTCS1: Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma (oral presentation)*
- *UCART22: Pre-clinical Activity of Allogeneic Anti-CD22 CAR T-Cells for the Treatment of B-cell Acute Lymphoblastic Leukemia (oral presentation)*
- *UCART123 product candidate targeting Blastic Plasmacytoid Dendritic Cell Neoplasm (poster presentation)*

### ***Corporate Governance***

On October 4, 2017, Mathieu Simon M.D., Executive VP and Chief Operating Officer, as been appointed as Interim Chief Medical Officer. In accepting this position, Dr. Simon



assumes the responsibilities of Loan Hoang-Sayag, who left Collectis to pursue other professional opportunities. Effective on October 11, 2017, Dr. Simon also resigned from his position as a member of the board of directors in order to focus on his additional responsibilities as Interim Chief Medical Officer.

## **Calyxt, Inc. – Collectis’ plant science subsidiary**

### ***Products***

Calyxt’s herbicide-tolerant wheat, its third wheat product candidate, and improved oil composition canola, its first canola product candidate, have advanced to Phase 1 of development. With these phase advancements, Calyxt now has a total of nine product candidates in Phase 1 of development or later across its five crops: soybeans, wheat, canola, potatoes and alfalfa.

The first of Calyxt’s two alfalfa product candidates has been designated as a non-regulated article under the “Am I Regulated?” Process by Biotechnology Regulatory Services of the Animal and Plant Health Inspection Service (APHIS), an agency of the USDA. The improved quality alfalfa is the sixth Calyxt product candidate to be confirmed as a non-regulated article by the USDA including its high oleic soybean, high oleic / low linolenic soybean, powdery mildew resistant wheat, cold storable potatoes and reduced browning potatoes.

### ***Corporate***

***Initial Public Offering:*** On July 25, 2017, Calyxt completed an initial public offering of its common stock, selling an aggregate of 8,050,000 shares of common stock at a price of \$8.00 per share (including 1,050,000 shares of common stock pursuant to the exercise by the underwriters of their option to purchase additional shares). Calyxt received net proceeds of approximately \$58.0 million, after deducting underwriting discounts and commissions and offering expenses. As part of the IPO, Collectis purchased 2,500,000 shares of common stock for a value of \$20.0 million, which is included in the net proceeds that Calyxt received. Calyxt used \$5.7 million of the proceeds to cover a portion of the outstanding obligations owed to Collectis. Following Calyxt’s IPO, Collectis owns 79.8% of the outstanding Calyxt’s common shares.

***Sale Leaseback Transaction:*** On September 6, 2017, Calyxt consummated a sale-leaseback transaction including a lease agreement between Calyxt and a third party with respect to the Calyxt’s lease of certain real property and improvements located in Roseville, Minnesota for a term of twenty years with option to extend the term for up to an additional twenty years.

***Headquarters Construction:*** Calyxt has broken ground on its new 40,000-square-foot headquarters, which will be housed on the 11-acre site in Roseville, together with state-of-the-art research completed approximately 11,000-square-foot greenhouses.

### **Financial Results**

Collectis’ consolidated financial statements have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International



Accounting Standards Board ("GAAP").

Effective in the third quarter of 2017, Collectis changed the presentation currency of its consolidated financial statements from the euro to the U.S. dollar, in order to enhance comparability with peers, which primarily present their financial statements in U.S. dollar.

### **Third quarter 2017 Financial Results**

**Cash:** As of September 30, 2017, Collectis had \$304.1 million in total cash, cash equivalents and current financial assets compared to \$271.2 million as of June 30, 2017. This increase of \$32.9 million reflects (i) an increase of \$38.0 million attributable to Calyxt IPO, (ii) the net cash provided by investing activities of \$6.1 million included \$7.0 million of proceeds from Calyxt's sale leaseback transaction and (iii) the unrealized positive translation effect of exchange rate fluctuations on U.S. dollar cash, cash equivalents and current financial assets of \$3.1 million; partially offset by (iv) the net cash flows used by operating activities of \$15.5 million.

Collectis expects that its cash, cash equivalents and current financial assets of \$304.1 million as of September 30, 2017 will be sufficient to fund its current operations into 2020.

**Revenues and Other Income:** During the quarters ended September 30, 2016 and 2017, we recorded \$12.6 million and \$7.3 million, respectively, in revenues and other income. This decrease of \$5.4 million is mainly due to (i) a \$5.0 million decrease in collaboration revenues of which \$4.0 million represented revenue from payments by Servier during the quarter ended September 30, 2016 for the supply of raw materials and batches of UCART19 products, that did not recur during the quarter ended September 30, 2017, \$0.6 million represented decreased recognition of upfront already paid to Collectis and a \$0.3 million decrease in research and development cost reimbursements, (ii) a \$0.2 million decrease in license revenue and (iii) a \$0.2 million decrease in research credit tax.

**Total Operating Expenses:** Total operating expenses for the third quarter of 2017 were \$33.0 million, compared to \$25.5 million for the third quarter of 2016. The non-cash stock-based compensation expenses included in these amounts were \$12.8 million and \$13.5 million, respectively.

**R&D Expenses:** For the quarters ended September 30, 2016 and 2017, research and development expenses increased by \$4.9 million from \$15.4 million in 2016 to \$20.3 million in 2017. Personnel expenses decreased by \$2.1 million from \$10.3 million in 2016 to \$8.1 million in 2017, primarily due to a \$2.3 million decrease in non-cash stock based compensation expense, partly offset by a \$0.2 million increase in wages and salaries. Purchases and external expenses increased by \$6.8 million from \$4.9 million in 2016 to \$11.7 million in 2017, mainly due to increased expenses related to payments to third parties participating in product development, purchases of biological raw materials, expenses for process development and expenses associated with the use of laboratories and other facilities. Other expenses increased by \$0.2 million for the third quarter of 2017 compared to the third quarter of 2016.

**SG&A Expenses:** During the quarters ended September 30, 2016 and 2017, we recorded \$9.7 million and \$12.2 million, respectively, of selling, general and administrative expenses. The increase of \$2.4 million primarily reflects an increase of \$2.2 million in



personnel expenses from \$7.4 million to \$9.6 million, attributable, among other things, to an increase of \$0.5 in wages and salaries and an increase of \$1.6 million in non-cash stock-based compensation expense, as well as an increase of \$0.3 million in purchases and external expenses.

**Financial Gain (Loss):** The financial loss was \$1.2 million for the third quarter of 2016 compared with a financial loss of \$3.4 million for the third quarter of 2017. The change in financial result was primarily attributable to an increase in net foreign exchange loss of \$3.2 million due to the effect of exchange rate fluctuations on our U.S. dollar cash and cash equivalent accounts, partially offset by an increase of \$0.8 million in fair value adjustment income on our foreign exchange derivatives and current financial assets and an increase of \$0.2 million in interest received from our financial investment.

**Net Income (Loss) Attributable to Shareholders of Collectis:** During the three months ended September 30, 2016 and 2017, we recorded a net loss attributable to shareholders of Collectis of \$14.1 million (or \$0.40 per share on both a basic and a diluted basis) and net loss attributable to shareholders of Collectis of \$26.2 million (or \$0.73 per share), respectively. Adjusted loss attributable to shareholders of Collectis for the third quarter of 2017 was \$13.3 million (\$0.37 per share) compared to adjusted loss attributable to shareholders of Collectis of \$0.5 million (\$0.02 per), for the third quarter of 2016. Adjusted income (loss) attributable to shareholders of Collectis for the third quarter of 2017 and 2016 excludes non-cash stock-based compensation expense of \$12.8 million and \$13.5 million, respectively. Please see "Note Regarding Use of Non-GAAP Financial Measures" for reconciliation of GAAP net income (loss) attributable to shareholders of Collectis to adjusted income (loss) attributable to shareholders of Collectis.

## First Nine Months 2017 Financial Results

**Cash:** As of September 30, 2017, Collectis had \$304.1 million in total cash, cash equivalents and current financial assets compared to \$ 291.2 million as of December 31, 2016. This increase of \$12.9 million primarily reflects (i) the proceeds of \$38.0 million as part of the Calyxt IPO, (ii) the net cash provided by investing activities of \$2.3 million which includes \$7.0 million of proceeds from Calyxt's sale leaseback transaction and (iii) the unrealized positive translation effect of exchange rate fluctuations on U.S. dollar cash, cash equivalents and current financial assets of \$13.1 million; partially offset by the net cash flows used by operating activities of \$42.8 million.

**Revenues and Other Income:** During the nine-month period ended September 30, 2016 and 2017, we recorded \$43.5 million and \$26.7 million, respectively, in revenues and other income. This decrease of \$16.8 million is mainly due to (i) a \$16.9 million decrease in collaboration revenues of which \$8.5 million represented one-time milestones revenues received during the second quarter of 2016 with the first patient dosed in the Phase 1 clinical trial for UCART 19, \$4.8 million represented decreased recognition of upfront fees already paid to Collectis and \$1.5 million represented decrease in research and development cost reimbursements and \$2.2 million represented decreased revenue from payment by Servier for the supply of raw materials and batches of UCART19 products, and (ii) a \$0.4 million



decrease in other licenses revenue, partially offset by (iii) an increase of \$0.5 million in research tax credits.

**Total Operating Expenses:** Total-operating expenses for the nine-month period ended September 30, 2017 were \$91.8 million, compared to \$90.3 million for the nine months ended September 30, 2016. The non-cash stock-based compensation expenses included in these amounts were \$38.9 million and \$44.5 million, respectively.

**R&D Expenses:** For the nine months ended September 30, 2016 and 2017, research and development expenses increased by \$0.3 million from \$58.3 million in 2016 to \$58.5 million in 2017. Personnel expenses decreased by \$8.5 million from \$36.4 million in 2016 to \$27.9 million in 2017, primarily due to a \$6.7 million decrease in non-cash stock based compensation expense, and a \$1.9 million decrease in social charges on stock options grants partly offset by a \$0.1 million increase in wages and salaries. Purchases and external expenses increased by \$8.4 million from \$20.7 million in 2016 to \$29.1 million in 2017, mainly due to increased expenses related to payments to third parties participating in product development, purchases of biological raw materials, expenses for process development and expenses associated with the use of laboratories and other facilities. Other expenses increased by \$0.4 million for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016.

**SG&A Expenses:** During the nine months ended September 30, 2016 and 2017, we recorded \$31.1 million and \$31.8 million, respectively, of selling, general and administrative expenses. The increase of \$0.8 million primarily reflects (i) an increase of \$1.1 million in personnel expenses from \$23.9 million to \$25.0 million, attributable to a \$1.6 million increase in wages and salaries, a \$1.1 million increase in non-cash stock based compensation expense, partly offset by a decrease of \$1.6 million of social charges on stock options grants, (ii) a \$0.2 increase in other expenses, partially offset by a \$0.5 million decrease in purchases and external expenses.

**Financial Gain (Loss):** The financial loss was \$7.1 million for the nine months ended September 30, 2016 compared with financial loss of \$10.0 million for the nine months ended September 30, 2017. The change in financial result was primarily attributable to the effect of exchange rate fluctuations on our U.S. dollar cash and cash equivalent accounts for \$7.3 million partially offset by the fair value adjustment on our derivative instrument and financial current asset for \$4.2 million and the interest received from our financial investment for \$0.2 million.

**Net Income (Loss) Attributable to Shareholders of Collectis:** During the nine months ended September 30, 2016 and 2017, we recorded a net loss attributable to shareholders of Collectis of \$53.9 million (or \$ 1.53 per share) and a net loss attributable to shareholders of Collectis of \$72.3 million (or \$2.03 per share), respectively. Adjusted loss attributable to shareholders of Collectis for the nine months ended September 30, 2017 was \$33.3 million (\$0.94 per share) compared to adjusted loss attributable to shareholders of Collectis of \$9.4 million (\$0.27 per share), for the nine months ended September 30, 2016. Adjusted loss attributable to shareholders of Collectis for the nine months ended September 30, 2017 and 2016 excludes a non-cash stock-based compensation expense of \$38.9 million and \$44.5 million, respectively. Please see "Note Regarding Use of Non-GAAP Financial Measures" for reconciliation of GAAP net income (loss) attributable to shareholders of Collectis to adjusted net income (loss) attributable to shareholders of Collectis.



CELLECTIS S.A.

INTERIM STATEMENT OF CONSOLIDATED FINANCIAL POSITION  
(\$ in thousands, except per share data)

	As of	
	December 31, 2016 Audited	September 30, 2017 Non audited
<b>ASSETS</b>		
<b>Non-current assets</b>		
Intangible assets	1 343	1 470
Property, plant, and equipment	16 900	8 229
Other non-current financial assets	691	989
<b>Total non-current assets</b>	<b>18 935</b>	<b>10 688</b>
<b>Current assets</b>		
Inventories	118	125
Trade receivables	3 627	2 897
Subsidies receivables	8 723	16 796
Other current assets	8 870	14 788
Cash and cash equivalent and Current financial assets	291 159	304 102
<b>Total current assets</b>	<b>312 498</b>	<b>338 707</b>
<b>TOTAL ASSETS</b>	<b>331 432</b>	<b>349 395</b>
<b>LIABILITIES</b>		
<b>Shareholders' equity</b>		
Share capital	2 332	2 365
Premiums related to the share capital	568 185	604 551
Treasury share reserve	(416)	(302)
Currency translation adjustment	(22 174)	(530)
Retained earnings	(207 875)	(251 413)
Net income (loss)	(67 255)	(72 266)
<b>Total shareholders' equity - Group Share</b>	<b>272 795</b>	<b>282 405</b>
Non-controlling interests	1 876	17 733
<b>Total shareholders' equity</b>	<b>274 671</b>	<b>300 138</b>
<b>Non-current liabilities</b>		
Non-current financial liabilities	30	17
Non-current provisions	560	697
<b>Total non-current liabilities</b>	<b>590</b>	<b>714</b>
<b>Current liabilities</b>		
Current financial liabilities	1 730	29
Trade payables	9 722	12 693
Deferred revenues and deferred income	38 929	29 763
Current provisions	594	923
Other current liabilities	5 196	5 135
<b>Total current liabilities</b>	<b>56 171</b>	<b>48 543</b>
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<b>331 432</b>	<b>349 395</b>



CELLECTIS S.A.

INTERIM STATEMENT OF CONSOLIDATED OPERATIONS – Third quarter  
(unaudited)  
(\$ in thousands, except per share data)

	For the three-month period ended September 30,	
	2016	2017
<b>Revenues and other income</b>		
Revenues	11 266	6 122
Other income	1 356	1 131
<b>Total revenues and other income</b>	<b>12 622</b>	<b>7 253</b>
<b>Operating expenses</b>		
Royalty expenses	(348)	(569)
Research and development expenses	(15 434)	(20 289)
Selling, general and administrative expenses	(9 726)	(12 153)
Other operating income and expenses	(15)	54
<b>Total operating expenses</b>	<b>(25 522)</b>	<b>(32 956)</b>
<b>Operating income (loss)</b>	<b>(12 900)</b>	<b>(25 703)</b>
<b>Financial gain (loss)</b>	<b>(1 156)</b>	<b>(3 393)</b>
<b>Net income (loss)</b>	<b>(14 056)</b>	<b>(29 096)</b>
Attributable to shareholders of Collectis	(14 056)	(26 154)
Attributable to non-controlling interests	-	(2 942)
<b>Basic net income (loss) attributable to shareholders of Collectis per share (\$/share)</b>	<b>(0.40)</b>	<b>(0.73)</b>
<b>Diluted net income (loss) attributable to shareholders of Collectis per share (\$/share)</b>	<b>(0.40)</b>	<b>(0.73)</b>



CELLECTIS S.A.

STATEMENT OF CONSOLIDATED OPERATIONS – FIRST NINE MONTHS

(unaudited)

(\$ in thousands, except per share data)

	For the nine-month period ended September 30,	
	2016	2017
<b>Revenues and other income</b>		
Revenues	36 702	19 416
Other income	6 754	7 286
<b>Total revenues and other income</b>	<b>43 456</b>	<b>26 702</b>
<b>Operating expenses</b>		
Royalty expenses	(1 155)	(1 748)
Research and development expenses	(58 269)	(58 525)
Selling, general and administrative expenses	(31 063)	(31 830)
Other operating income and expenses	186	317
<b>Total operating expenses</b>	<b>(90 300)</b>	<b>(91 787)</b>
<b>Operating income (loss)</b>	<b>(46 844)</b>	<b>(65 085)</b>
<b>Financial gain (loss)</b>	<b>(7 061)</b>	<b>(9 969)</b>
<b>Net income (loss)</b>	<b>(53 905)</b>	<b>(75 054)</b>
Attributable to shareholders of Collectis	(53 905)	(72 266)
Attributable to non-controlling interests	--	(2 788)
<b>Basic net income (loss) attributable to shareholders of Collectis per share (\$/share)</b>	<b>(1.53)</b>	<b>(2.03)</b>
<b>Diluted net income (loss) attributable to shareholders of Collectis per share (\$/share)</b>	<b>(1.53)</b>	<b>(2.03)</b>



## Note Regarding Use of Non-GAAP Financial Measures

Collectis S.A. presents adjusted net income (loss) attributable to shareholders of Collectis in this press release. Adjusted net income (loss) attributable to shareholders of Collectis is not a measure calculated in accordance with IFRS. We have included in this press release a reconciliation of this figure to Net income (loss) attributable to shareholders of Collectis, which is the most directly comparable financial measure calculated in accordance with IFRS. Because adjusted net income (loss) attributable to shareholders of Collectis excludes Non-cash stock-based compensation expense—a non-cash expense, we believe that this financial measure, when considered together with our IFRS financial statements, can enhance an overall understanding of Collectis' financial performance. Moreover, our management views the Company's operations, and manages its business, based, in part, on this financial measure. In particular, we believe that the elimination of Non-cash stock-based expenses from Net income (loss) attributable to shareholders of Collectis can provide a useful measure for period-to-period comparisons of our core businesses. Our use of adjusted net income (loss) attributable to shareholders of Collectis has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our financial results as reported under IFRS. Some of these limitations are: (a) other companies, including companies in our industry which use similar stock-based compensation, may address the impact of Non-cash stock-based compensation expense differently; and (b) other companies may report adjusted net income (loss) attributable to shareholders or similarly titled measures but calculate them differently, which reduces their usefulness as a comparative measure. Because of these and other limitations, you should consider adjusted net income (loss) attributable to shareholders of Collectis alongside our IFRS financial results, including Net income (loss) attributable to shareholders of Collectis.

### RECONCILIATION OF GAAP TO NON-GAAP NET INCOME – Third quarter (unaudited) (\$ in thousands, except per share data)

	For the three-month period ended September 30,	
	2016	2017
<b>Net net income (loss) attributable to shareholders of Collectis</b>	<b>(14 056)</b>	<b>(26 154)</b>
Adjustment:		
Non-cash stock-based compensation expense	13 526	12 810
<b>Adjusted net income (loss) attributable to shareholders of Collectis</b>	<b>(531)</b>	<b>(13 344)</b>
<b>Basic Adjusted net income (loss) attributable to shareholders of Collectis (\$/share)</b>	<b>(0.02)</b>	<b>(0.37)</b>
<b>Weighted average number of outstanding shares, basic (units)</b>	<b>35 333 572</b>	<b>35 917 975</b>
<b>Diluted Adjusted net income (loss) attributable to shareholders of Collectis (\$/share)</b>	<b>(0.02)</b>	<b>(0.37)</b>
<b>Weighted average number of outstanding shares, diluted (units)</b>	<b>35 713 432</b>	<b>35 938 145</b>



**RECONCILIATION OF GAAP TO NON-GAAP NET INCOME – First nine months**

(unaudited)  
(\$ in thousands, except per share data)

	For the nine-month period ended September 30,	
	2016	2017
<b>Net net income (loss) attributable to shareholders of Collectis</b>	<b>(53 905)</b>	<b>(72 266)</b>
Adjustment: Non-cash stock-based compensation expense	44 534	38 940
<b>Adjusted net income (loss) attributable to shareholders of Collectis</b>	<b>(9 371)</b>	<b>(33 325)</b>
<b>Basic Adjusted net income (loss) attributable to shareholders of Collectis (\$/share)</b>	<b>(0.27)</b>	<b>(0.94)</b>
<b>Weighted average number of outstanding shares, basic (units)</b>	<b>35 274 890</b>	<b>35 604 374</b>
<b>Diluted Adjusted net income (loss) attributable to shareholders of Collectis (\$/share)</b>	<b>(0.27)</b>	<b>(0.94)</b>
<b>Weighted average number of outstanding shares, diluted (units)</b>	<b>35 695 907</b>	<b>35 626 736</b>

**About Collectis**

Collectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 17 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Collectis uses the power of the immune system to target and eradicate cancer cells. Using its life-science-focused, pioneering genome engineering technologies, Collectis’ goal is to create innovative products in multiple fields and with various target markets. Collectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Euronext Growth market (ticker: ALCLS). To find out more about us, visit our website: [www.collectis.com](http://www.collectis.com)

Talking about gene editing? We do it. TALEN® is a registered trademark owned by Collectis.

**For further information, please contact:**

**Media contacts:**

Jennifer Moore, VP of Communications, 917-580-1088, [media@collectis.com](mailto:media@collectis.com)

Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241, [ckasunich@kcsa.com](mailto:ckasunich@kcsa.com)



**IR contact:**

Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008,  
simon.harnest@collectis.com

**Cautionary Statement Regarding Forward-Looking Statements**

This press release contains certain “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions and include, but are not limited to, statements regarding the outlook for Collectis’ future business and financial performance. Forward-looking statements are based on management’s current expectations and assumptions, which are subject to inherent uncertainties, risks and changes in circumstances, many of which are beyond Collectis’ control. Actual outcomes and results may differ materially due to global political, economic, business, competitive, market, regulatory and other factors and risks. Collectis expressly disclaims any obligation to update or revise any of these forward-looking statements, whether because of future events, new information, a change in its views or expectations, or otherwise.